{
    "SPADE_N_13771": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_N_13771",
            "Peptide Name": "DMS-PS2 (Dermaseptin; XXA; UCLL1c; natural AMPs; frog, amphibians, animals; BBMm)",
            "Source": "Skin secretion, the waxy monkey leaf frog or waxy monkey tree frog,Phyllomedusa sauvagei, Argentina, Bolivia, Paraguay and Brazil, South America",
            "Family": "Not found",
            "Gene": "Not found",
            "Sequence": "ALWKTLLKNVGKAAGKAVLNAVTDMVNQ",
            "Sequence Length": 28,
            "UniProt Entry": "Ref",
            "Protein Existence": "Not found",
            "Biological Activity": [
                "Anti-Gram+",
                "Anti-Gram-",
                "Antifungal",
                "Antifungal",
                "Anti-MRSA",
                "Antibiofilm"
            ],
            "Target Organism": "Not found",
            "Hemolytic Activity": "Not found",
            "Cytotoxicity": "Not found",
            "Binding Target": "Not found",
            "Linear/Cyclic": "Not found",
            "N-terminal Modification": "Not found",
            "C-terminal Modification": "Not found",
            "Stereochemistry": "Not found",
            "Structure Description": "Not found",
            "Formula": "Not found",
            "Mass": 2954.49,
            "PI": 10.0,
            "Hydrophobicity": 0.24,
            "Half Life": "Not found",
            "Function": "Not found",
            "Literature": [
                {
                    "Author": "Song X, Pan H, Wang H, Liao X, Sun D, Xu K, Chen T, Zhang X, Wu M, Wu D, Gao Y.2020",
                    "Reference": "Acta Biomater. 2020 Jun;109:208-219. doi: 10.1016/j.actbio.2020.03.024.PubMed",
                    "Title": "Identification of new dermaseptins with self-assembly tendency: membrane disruption, biofilm eradication, and infected wound healing efficacy."
                }
            ],
            "Frequent Amino Acids": "AKL",
            "Absent Amino Acids": "CEFHIOPRSUY",
            "Basic Residues": 4,
            "Acidic Residues": 1,
            "Hydrophobic Residues": 15,
            "Polar Residues": 19,
            "Positive Residues": 4,
            "Negative Residues": 1,
            "Net Charge": 3,
            "Comments": "APD analysis reveals this sequence is most similar (96.43%) toDermaseptin-DI2V=L=K=14%; N:11%; A:18%; Mol formula:  C132H229N34O37S1; Mol Wt: 2954.52; Mol Ex Coeff: 5550; GRAVY:  0.239.Activity:  active against S. aureus NCTC 10788 (MIC 8 ug/ml), MRSA NCTC 12493 (MIC 16 ug/ml), MRSA (ATCC 43300) (MIC 8 ug/ml), C. albicans NCYC 1467 (MIC 16 ug/ml), E. coli (NCTC 10418) (MIC 8 ug/ml), and P. aeruginosa (ATCC 27853) (MIC 16 ug/ml). Also biofilm inhibition and disruption properties (S. aureus MBIC 16 ug/ml; MBEC 64 ug/ml; E. coli MBIC 16 ug/ml; MBEC 512 ug/ml; P. aeruginosa  MBIC 256 ug/ml; MBEC 512 ug/ml). SLighly more active than DMS-PS1 since it's more hydrophobic.Structure:  helical in 50% TFE or SDS micelles.MOA:  The helical structure is responsible for membrane damage.Animal model:mouse: wound healing: peptide treatment led to both CFU drop of MRSA and healing.",
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_N_01172",
                    "Similarity": 0.9642857142857143,
                    "Sequence": "ALWKTLLKNVGKAAGKAALNAVTDMVNQ"
                },
                {
                    "SPADE_ID": "SPADE_N_06874",
                    "Similarity": 0.9285714285714286,
                    "Sequence": "ALWKSLLKNVGKAAGKAALNAVTDMVNQ"
                },
                {
                    "SPADE_ID": "SPADE_N_12448",
                    "Similarity": 0.9285714285714286,
                    "Sequence": "ALWKDLLKNVGKAAGKAVLNKVTDMVNQ"
                }
            ]
        }
    }
}